Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc. is a global commercial-stage biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. Its products include ONPATTRO, GIVLAARI, and OXLUMO. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Alnylam Pharmaceuticals reports robust 2022 performance and growth opportunities

Alnylam Pharmaceuticals had a strong financial performance in 2022, driven by the success of AMVUTTRA and advancements in ATTR amyloidosis treatments.
While facing challenges such as FDA requests and the need for self-sustainability, the company is poised for growth with projected revenues and pipeline opportunities.
Opportunities lie in market expansion, innovative pipeline programs, and upcoming regulatory milestones, positioning Alnylam for continued success in RNAi therapeutics.

Alnylam Pharmaceuticals posts robust Q1 growth despite FDA challenges

Alnylam Pharmaceuticals reported strong financial performance in Q1 2023, driven by the TTR franchise and key product sales growth. Despite challenges with the FDA's partial clinical hold, the company remains optimistic about pipeline development and addressing unmet patient needs with RNAi therapeutics.

Alnylam Pharmaceuticals excels in Q2, poised for growth and innovation

Alnylam Pharmaceuticals delivered strong financial results, positive clinical data, and strategic partnerships in Q2 2023, positioning itself for continued growth.
While facing challenges such as market competition and regulatory complexities, Alnylam remains focused on innovation, patient care, and commercial success.
The company's emphasis on R&D, market positioning, and leveraging its RNAi platform underscores its commitment to advancing therapies and driving value for stakeholders.

Alnylam Pharmaceuticals reports robust Q3 growth and eyes HELIOS-B opportunities

Alnylam Pharmaceuticals delivered strong financial results in Q3 2023, showcasing growth and innovation in its product portfolio and pipeline. Despite challenges, the company remains focused on long-term strategies and seizing opportunities in the evolving healthcare landscape.

Alnylam Pharmaceuticals excels in 2023, poised for market leadership

Alnylam Pharmaceuticals demonstrated strong financial performance in 2023, with notable achievements in commercial RNAi therapeutics and franchise growth. The company's strategic focus on innovation, study optimization, and market positioning bodes well for future success and market leadership in RNAi therapeutics.

Alnylam Pharmaceuticals reports robust Q1 performance and strategic readiness

Alnylam Pharmaceuticals showcased strong financial performance, strategic focus on patient needs, and readiness for upcoming milestones.
While facing challenges in meeting guidance and ensuring successful launches, the company is well-positioned for growth and innovation.
Opportunities lie in upcoming milestones, secondary endpoint focus, and future catalysts, driving potential value creation and differentiation.

Alnylam Pharmaceuticals excels in Q2 2024, poised for sustained growth

Alnylam Pharmaceuticals demonstrated strong financial performance and clinical advancements in Q2 2024, driven by key revenue growth drivers and pipeline progress.
While facing challenges such as rising expenses, the company's strategic strengths in franchise performance and margin improvement position it well for future opportunities.
With upcoming milestones and increased guidance, Alnylam is poised to capitalize on growth prospects and maintain its position as a leader in rare disease therapeutics.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

CME Group

CRISPR Therapeutics

iShares Nasdaq Biotechnology ETF

NVIDIA

In 5 years, you be selling your gold and buying more companies leading the century of biology.

Trade of the 2020's: Sell Gold, Buy Biotech

Alnylam (NASDAQ: ALNY) is a U.S.-based biopharma company primarily developing RNA interference drugs.

Why Has Alnylam’s Stock Gained 25% In The Last Two Weeks

The RNAi pioneer earned a surprise drug approval. It could have far-reaching implications for the company's future.

Here's Why Alnylam Pharmaceuticals Rose 35.1% in November

Investors were caught off guard when the genetic medicines company earned marketing approval for its second RNAi drug product sooner than expected.

Does a Surprise Approval Make Alnylam Pharmaceuticals a Buy?

Alnylam (ALNY) gets FDA approval for givosiran injection for subcutaneous use to treat adults with acute hepatic porphyria. Givosiran injection will be marketed by the trade name of Givlaari.

Alnylam Gets Second Product Approval Amid Stiff Competition

BeiGene

Global Blood Therapeutics

Novartis

Vertex Pharmaceuticals

Here's why the FDA recently approved five new drugs way ahead of schedule.

5 New Drug Approvals the FDA Gave Top Priority

ARK Genomic Revolution Multi-Sector ETF

Tesla

SPDR Gold Trust

Why Gold is Headed to Zero -- And What You Should Buy Instead

As of late, it has definitely been a great time to be an investor in Alnylam Pharmaceuticals, Inc. (ALNY).

Alnylam Pharmaceuticals, Inc. (ALNY) Shares March Higher, Can It Continue?

Alnylam Pharmaceuticals Sheds Some Light On Its Expanding Early-Stage Opportunities

This biotech's impressed the FDA, but what about shareholders?

Is Alnylam Stock a Good Buy Now?

Alnylam Pharmaceuticals is coming of age.

Second RNAi Drug Approved: Biotech Investors Should Pay Attention to This New Drug Class

Alnylam (ALNY) gets FDA approval for givosiran injection, to be marketed by the trade name of Givlaari, for the treatment of adults with AHP.

Alnylam's Givosiran Gets FDA Nod for Acute Hepatic Porphyria

Alnylam Pharmaceuticals Secures Its Second Approval, And The Pipeline Is Still Attractive

Alnylam (ALNY) saw a big move last session, as its shares jumped nearly 11% on the day, amid huge volumes.

Alnylam (ALNY) Catches Eye: Stock Jumps 10.5%

Shares of Alnylam Pharmaceuticals Inc. ALNY, +10.50% were up 9% in afternoon trading after the Food and Drug Administration approved Givlaari, its treatment for acute hepatic porphyria, a rare, genetic metabolic disorder.

Alnylam shares jump on FDA approval

Alnylam (ALNY) incurs narrower-than-expected loss and beats sales estimates in the third quarter of 2019.

Alnylam's (ALNY) Q3 Earnings and Revenues Beat Estimates

Alnylam Pharmaceuticals' (ALNY) CEO John Maraganore on Q3 2019 Results - Earnings Call Transcript

Akcea Therapeutics

Eidos Therapeutics Inc

Ionis Pharma

The sales figure for Vyndaqel shows the market potential for several smaller players' pipeline candidates.

These Biotechs Were Focused on One Line on Pfizer’s Earnings Report

Alnylam (ALNY) delivered earnings and revenue surprises of 11.52% and 14.15%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Alnylam Pharmaceuticals (ALNY) Reports Q3 Loss, Tops Revenue Estimates

Alnylam (ALNY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings.

Why Earnings Season Could Be Great for Alnylam (ALNY)

Alnylam (ALNY) is on track with the development of its pipeline despite stiffening competition.

Alnylam Focuses on Pipeline Development Amid Competition

Alnylam (ALNY) starts phase III APOLLO-B study on its lead drug Onpattro for treating transthyretin amyloidosis with cardiomyopathy. Shares rise.

Alnylam Begins Phase III Study on Onpattro for New Indication

Aimmune Therapeutics

Moderna

Investors better get ready for a busy week ahead.

3 Biotech Stocks That Could Soar This Week

Alnylam (ALNY) reported earnings 30 days ago. What's next for the stock?

Why Is Alnylam (ALNY) Up 2.3% Since Last Earnings Report?

Alnylam exceeded expectations for Q2 Onpattro sales, but the competitive impact of Pfizer's tafamidis is still a major worry for some investors.

News for Alnylam Pharmaceuticals Stock (ALNY)